We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
One in six men over 50 have symptoms of testosterone deficiency, but too few of them receive appropriate treatment, said Grünenthal CEO Gabriel Baertschi. Read More
Novo Nordisk’s Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, shows better efficacy for weight loss than its peers but it requires a significant discount to be cost-effective, according to a new analysis from the Institute for Clinical and Economic Review (ICER). Read More
Catalyst Pharmaceuticals has settled with Jacobus Pharmaceutical over claims that Jacobus’ Lambert-Eaton myasthenic syndrome (LEMS) drug Ruzurgi (amifampridine) infringed on its patent rights for Firdapse (amifampridine). Read More
Zynlonta was granted FDA accelerated approval in April 2021 as a single-agent intravenous treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. Read More
Bristol Myers Squibb (BMS) has settled with Alembic Pharmaceuticals over allegations that Alembic’s proposed generic drug infringed on its blockbuster blood cancer drug Revlimid (lenalidomide). Read More